Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed its Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.